Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17935182 | 0.86 | CARM1 (0.33) | CHRM2PIK3CD | |
| SCHEMBL19936946 | 0.82 | GGPS1 (0.41) | GGPS1PIK3CD | |
| SCHEMBL23567936 | 0.80 | LMNA (0.39) | GGPS1PIK3CD | |
| SCHEMBL23505460 | 0.80 | GGPS1 (0.48) | CHRM2GGPS1PIK3CD | |
| SCHEMBL10704491 | 0.79 | CHRM2 (0.50) | CHRM2GGPS1PIK3CDTDP1 | |
| SCHEMBL27334232 | 0.78 | GGPS1 (0.52) | CHRM2GGPS1 | |
| SCHEMBL21733336 | 0.78 | GGPS1 (0.35) | GGPS1PIK3CD | |
| SCHEMBL28419369 | 0.77 | CHRM2 (0.48) | CHRM2PIK3CDTDP1 | |
| SCHEMBL22856338 | 0.77 | LMNA (0.41) | CHRM2GGPS1PIK3CD | |
| SCHEMBL19264171 | 0.77 | GGPS1 (0.46) | CHRM2GGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022147465-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| US-10662193-B2 | Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins | AC IMMUNE SA (CH) | 2020-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662193-B2 | Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins | APP, BACE1, PSEN1 | CHRM2 146/4885GGPS1 3062/4885PIK3CD 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.